title: Extent and content of data for regulatory submissions: First-in-human and marketing authorization--Viewpoint of US industry.
abstract: The amount and type of data in regulatory submissions increases dramatically from the first-in-human clinical trials application through to the extensive dossier that is required for marketing authorization. The Pharmaceuticals and Biotechnology industries are very familiar with the requirements and expectations of Health Authorities for small molecule and biologics, but have limited experience for cell-based therapies. Fortunately, the United States Food and Drug Administration (FDA) and European Medicines agency (EMA) Committee for Advanced Therapies (CAT) have considerable experience in regulating cell therapies and have provided extensive Guidance documents for developers. The Agencies offers advice to Sponsors through a variety of meetings. However, it is incumbent on the Sponsor to understand the regulations, interpret the Guidance documents and formulate clear company positions to enable the Agency to provide clear feedback. It is important for Sponsors to understand the factors that are critical for the safety and efficacy of their product and to demonstrate to the Health Authorities that they have a control strategy that ensures safety and efficacy during all stages of development. The focus of this paper is to describe some of the challenges for the chemistry manufacturing and controls (CMC) for cell therapies being development internationally.
authors.affiliation: Janssen Research & Development LLC, USA. Electronic address: Iharris@its.jnj.com.
authors.forename: Ian Ross
authors.initials: IR
authors.lastname: Harris
mesh_terms: D064987:Cell- and Tissue-Based Therapy; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence*; D005060:Europe; D006801:Humans; D014481:United States
keywords: CMC; Cell therapy; Regulatory